STAGE IIIB LUNG CANCER AJCC V8
Clinical trials for STAGE IIIB LUNG CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB LUNG CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIB LUNG CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Threat treatment trial aims to keep aggressive lung cancer at bay
Disease control OngoingThis trial is testing a combination of three drugs (niraparib, temozolomide, and atezolizumab) to see if they work better together to control advanced cancers, especially a type called extensive-stage small cell lung cancer. The study first finds a safe dose, then compares the th…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
One-Two punch for lung cancer: can zapping tumors boost drug power?
Disease control OngoingThis study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It tests if taking the targeted drug osimertinib for 6-12 weeks, then adding focused radiation therapy or surgery to remaining tumors, works better at keeping the…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Radiation boost for tough lung cancers: can it extend lives?
Disease control TerminatedThis study is for people with advanced non-small cell lung cancer that has low levels of a marker called PD-L1. It compares the standard immunotherapy treatment (with or without chemo) to the same treatment plus a short course of radiation. The goal is to see if adding radiation …
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Cancer treatment moves home: trial tests telemedicine for lung cancer care
Disease control OngoingThis study is testing whether a lung cancer immunotherapy drug can be safely and effectively given at home by a visiting nurse, with most doctor visits done remotely via video call. It involves patients with non-small cell lung cancer who are eligible for the drug atezolizumab. T…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
One-Shot radiation tested to zap remaining lung cancer cells
Disease control OngoingThis study is testing a new, faster way to give radiation after surgery for non-small cell lung cancer. Instead of weeks of daily treatments, doctors give one powerful, highly focused dose to try to kill any leftover cancer cells while aiming to spare healthy lung tissue. The mai…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug duo aims to control Tough-to-Treat lung cancers
Disease control OngoingThis study is testing whether combining two drugs, niraparib and dostarlimab, can help control recurrent small cell lung cancer and other aggressive neuroendocrine cancers. It is for adults whose cancer has returned after at least one prior treatment. The goal is to see if this c…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for lung cancer patients after standard treatment fails
Disease control OngoingThis early-stage study is testing whether adding an experimental drug called minnelide to an existing lung cancer medication (osimertinib) is safe and might help patients whose cancer has continued to grow. The trial is for adults with advanced non-small cell lung cancer that has…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Zapping lung cancer: heat vs. scalpel in Head-to-Head trial
Disease control OngoingThis study is comparing two standard ways to treat small lung tumors: a minimally invasive procedure that uses microwave energy to heat and destroy the tumor, and a small surgery to cut it out. Researchers want to see which method is safer, more effective at keeping the cancer fr…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Doctors test Immune-Boosting drugs with radiation to fight lung cancer
Disease control OngoingThis early-stage study is testing whether two immunotherapy drugs (ipilimumab and nivolumab) can be safely combined with radiation therapy for patients with stage II or III non-small cell lung cancer. The goal is to see if this combination helps the immune system attack the cance…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat lung cancer: testing a Triple-Drug attack
Disease control OngoingThis study is testing if adding a new drug called pevonedistat to two standard chemotherapy drugs (carboplatin and paclitaxel) works better for people with advanced non-small cell lung cancer. It is for adults whose cancer has gotten worse after treatment with immunotherapy. The …
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Major trial aims to boost survival for Tough-to-Treat lung cancer
Disease control OngoingThis large study is testing if starting an immunotherapy drug called durvalumab earlier, alongside standard chemotherapy and radiation, works better for people with stage 3 non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this approach helps pat…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Cancer vaccine teams up with immune drugs in fight against advanced tumors
Disease control OngoingThis trial is testing whether combining an experimental cancer vaccine (CIMAvax) with approved immunotherapy drugs (nivolumab or pembrolizumab) is safe and more effective for treating advanced non-small cell lung cancer or squamous head and neck cancer. The study aims to find the…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Scientists test supercharged cord blood cells as new weapon against tough lung cancers
Disease control OngoingThis early-stage study is testing a new type of cell therapy for people with advanced non-small cell lung cancer that has spread and no longer responds to standard immunotherapy. Researchers are giving patients specially modified immune cells (called NK cells) taken from umbilica…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug duo aims to outsmart resistant lung cancer
Disease control OngoingThis trial is testing whether adding a new drug called LY3295668 to an existing lung cancer drug (osimertinib) can help control cancer that has stopped responding to standard treatment. It involves 32 adults with a specific type of advanced lung cancer (EGFR-mutant non-small cell…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New combo attack on tough lung cancers
Disease control OngoingThis study is testing a combination of two drugs, trametinib and pembrolizumab, for people with advanced non-small cell lung cancer that has come back or spread after previous treatments. The goal is to see if the drugs work better together to control the cancer and to find the s…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Major trial tests new strategy to control advanced lung cancer
Disease control OngoingThis large, late-stage trial aims to find the best way to combine immunotherapy and chemotherapy for patients with advanced non-squamous lung cancer. It will compare starting with immunotherapy alone versus starting with both treatments together, and test different approaches if …
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New cancer combo aims to supercharge immune system while taming side effects
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New drug duo tested for Tough-to-Treat lung cancer
Disease control OngoingThis early-phase study is testing a combination of two drugs, brigatinib and bevacizumab, for patients with a specific type of advanced lung cancer (ALK-positive) that has worsened despite prior targeted therapy. The main goals are to find the safest dose and understand the side …
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
New nanoparticle tested to boost radiation against tough lung cancer
Disease control OngoingThis early-stage study is testing a new drug called NBTXR3, given as an injection directly into lung tumors, along with radiation therapy. The goal is to find the safest dose and see if the drug helps the radiation work better to kill cancer cells in people whose non-small cell l…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 14:00 UTC
-
New combo therapy aims to stop lung Cancer's comeback
Disease control TerminatedThis large study is testing if adding a new pill (AZD6738) to a standard immunotherapy drug (durvalumab) is better at keeping cancer from coming back in people with certain stages of non-small cell lung cancer. It's for patients who have already had chemotherapy and surgery, but …
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Feb 27, 2026 15:06 UTC
-
Nurses tackle the hidden fear that haunts advanced cancer patients
Symptom relief OngoingThis study is testing whether a special program led by nurses can help people with advanced lung or gynecologic cancer cope with intense fears about their illness getting worse. Participants will have five short video sessions over six weeks to learn worry management skills, set …
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Mar 30, 2026 14:31 UTC
-
Virtual nurse coaches aim to improve life after cancer
Symptom relief OngoingThis study is testing a telehealth program designed to help people who have finished treatment for early-stage lung or colorectal cancer. It compares a special coaching program that teaches self-management skills to standard educational materials. The goal is to see if the coachi…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Mar 23, 2026 15:17 UTC
-
Virtual therapy tested to ease lung cancer distress
Symptom relief OngoingThis study is testing an online support program designed to help women with lung cancer feel better emotionally and manage their symptoms. Participants are assigned to either a group learning mindfulness and coping skills or a group receiving educational information about lung ca…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Mar 20, 2026 14:48 UTC
-
New hope for cancer patients struggling to eat
Symptom relief OngoingThis study is testing whether a medication called anamorelin can help improve appetite and prevent weight loss in people with advanced lung cancer who have poor appetite. Researchers will compare anamorelin against a placebo (inactive pill) in 25 patients over 9 weeks. The study …
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Mar 16, 2026 15:25 UTC
-
Can we predict who gets nerve damage from chemo?
Knowledge-focused OngoingThis study aims to create a tool to predict which cancer patients are most likely to develop nerve damage (like tingling or numbness in hands and feet) from a common class of chemotherapy drugs called taxanes. Researchers will follow over 1,300 patients with breast, lung, or ovar…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Massive study maps lung cancer genes to personalize future care
Knowledge-focused OngoingThis large study aims to understand the genetic makeup of lung cancer tumors after they have been surgically removed. It will test tumor samples from 8,300 patients with early-stage non-small cell lung cancer to identify specific genetic changes. The goal is to use this genetic i…
Matched conditions: STAGE IIIB LUNG CANCER AJCC V8
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC